Built to find what cancer is hiding.

What we believe

No patient should miss a treatment opportunity because the right biomarker could not be found

Arima Genomics is a cancer diagnostics company built on deep expertise in 3D genome science and Hi-C sequencing technology. We develop clinical tests and technology platforms that uncover cancer-driving alterations conventional approaches were not built to detect — helping bring more patients closer to the right treatment.

Our Vision

A future where every patient has the genomic answers needed to guide the right treatment.

Our Mission

To improve patient outcomes by uncovering cancer-driving genomic alterations and translating them into actionable insights for therapy selection.

Our Story

Arima began in 2015 with a focus on understanding how DNA is organized and regulated in three dimensions. That foundation gave Arima a different view of the cancer genome — and a way to detect structural signals that conventional approaches leave unresolved.

In 2022, that science changed the company’s trajectory. A tumor sample from a teenage girl with glioblastoma came to Arima after extensive DNA and RNA profiling had failed to identify an actionable driver. Using Arima’s Hi-C-based approach, the team identified a cancer-driving alteration other methods had missed. The finding helped point to a new treatment option, and the patient continues to do well.

That case crystallized Arima’s purpose: cancer diagnostics must evolve to capture more of what drives disease. Today, Arima applies Hi-C sequencing through Aventa clinical tests for solid tumors and lymphoma, while advancing the platform and evidence needed to redefine cancer diagnostics and reveal more of what drives cancer.